<DOC>
	<DOC>NCT01235403</DOC>
	<brief_summary>To evaluate if a flexible dose escalation of lacosamide, up to the maximum approved dose of 400 mg/day, or to a clinically effective lower dose for an individual patient, improves the tolerability and safety of lacosamide (200 mg to 400 mg/d) as add-on treatment for patients with partial onset epilepsy. Explanation of acronym: SELF = Safety Efficacy Lacosamide Flexibility</brief_summary>
	<brief_title>Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Patient has a diagnosis of partialonset epilepsy with or without secondary generalization Currently taking 1 to 3 concomitant marketed antiepileptic drugs 18 years and older at study entry Previous use of lacosamide Hypersensitivity to any component of lacosamide Patients with partial onset seizures not clearly identifiable History of generalized epilepsy History of status epilepticus within last 12 months Uncountable seizures due to clustering within last 12 weeks Non epileptic events, including pseudoseizures, conversion disorder that could be confused with seizures History of drug or alcohol abuse History of suicide attempt Progressive cerebral disease Concomitant treatment of felbamate Prior or concomitant vigabatrin use Under legal protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Epilepsy treatment.</keyword>
	<keyword>Anti-epileptic drugs</keyword>
	<keyword>Seizures</keyword>
</DOC>